Course and outcome of depressive disorders in primary care: a prospective 18-month study

M. S. Vuorilehto^{1,2}, T. K. Melartin^{1,3} and E. T. Isometsä^{1,4*}

¹ Department of Mental Health and Alcohol Research, National Public Health Institute, Finland

² Primary Health Care Organization of the City of Vantaa, Finland

⁸ Department of Psychiatry, HUCH, Peijas Hospital, Finland

⁴ Department of Psychiatry, University of Helsinki, Finland

Background. Depressive disorders are known to often be chronic and recurrent both in the general population and in psychiatric settings. However, despite its importance for public health and services, the outcome of depression in primary care is not well known.

Method. In The Vantaa Primary Care Depression Study (PC-VDS), 1111 consecutive primary-care patients were screened for depression with the Prime-MD screen, and 137 diagnosed with DSM-IV depressive disorders by interviewing with the Structured Clinical Interview for DSM-IV (SCID)-I/P and SCID-II. This cohort was prospectively followed-up at 3, 6 and 18 months. Altogether 123 patients (90%) completed the 18-month follow-up, including 79 with major depressive disorder (MDD) and 44 with subsyndromal disorders. Duration of the index episode and the timing of relapses/recurrences were examined using a life-chart.

Results. Of the patients with MDD, only a quarter [25% (20/79)] achieved and remained in full remission, while another quarter [25% (20/79)] persisted in major depressive episode for 18 months. The remaining 49% (39/79) suffered from residual symptoms or recurrences. In Cox regression models, time to remission and recurrences were robustly predicted by severity of depression, and less consistently by co-morbid substance-use disorder, chronic medical illness or cluster C personality disorder. Of the subsyndromal patients, 25% (11/44) proceeded to MDD.

Conclusions. This prospective medium-term study verified the high rate of recurrences and chronicity of depression also in primary care. Severity of depressive symptoms and co-morbidity are important predictors of outcome. Development of chronic disease management for depression is warranted in primary care.

Received 22 November 2007; Revised 15 October 2008; Accepted 4 December 2008; First published online 2 March 2009

Key words: Co-morbidity, depression, episode duration, outcome, primary care, recurrence, severity of depression.

Introduction

Depression is a highly prevalent condition with marked personal, social and economic consequences (Spijker *et al.* 2001; Kessler *et al.* 2003; Hasin *et al.* 2005; Moussavi *et al.* 2007). Its chronic and recurrent nature has been shown both in the general population (Keller *et al.* 1992; Eaton *et al.* 1997; Spijker *et al.* 2001; Pirkola *et al.* 2005) and in psychiatric settings (Keller *et al.* 1992; Melartin *et al.* 2004), but only a few studies have reported the course and outcome of depression in primary health care. While information on outcome and predictors for chronicity and recurrence in primary care is of major importance for rational planning of treatment and services, it is currently largely missing.

The few existing studies on outcome of depression in primary care have significant limitations (Table 1), the most important of which is the almost exclusively cross-sectional nature of reported outcome, i.e. reporting only the status of the patient at the end of the follow-up period, thus ignoring relapses, recurrences and chronicity. Bearing in mind this shortage, naturalistic medium-term follow-ups have suggested full recovery from major depressive disorder (MDD) in a quarter to one-half of patients, and chronic course in a third (Ormel et al. 1993; Gaynes et al. 1999; Wagner et al. 2000; Lyness et al. 2002; van den Brink et al. 2002; Barkow et al. 2003; De Almeida Fleck et al. 2005). Moreover, up to one-fifth of subthreshold forms of depression appear to proceed to a major depressive episode (MDE) (Wagner et al. 2000; Lyness et al. 2002). Outcome has also been reported for control groups of intervention studies (Table 1). Although their findings

^{*} Address for correspondence : E. T. Isometsä, M.D., Ph.D., Department of Psychiatry, Institute of Clinical Medicine, PO Box 22, 00014 University of Helsinki, Helsinki, Finland.

⁽Email: erkki.isometsa@hus.fi)

Source	Patients with MDD/ patients with subMDD	Age, years	Screening method and possible other inclusion criteria	Baseline diagnostic method	Number of assessments/ life-chart if used	Time of follow-up, months	Characteristics assessed at baseline				
							Severity of depression	Duration of current depressive episode	Recurrence	Co-morbid Axis I/II/III disorders	Definition of cross-sectional outcome
Naturalistic pro	ospective stu	ıdies									
Barkow <i>et al.</i> (2003)	725/-	18–65	GHQ-12	CIDI-PHC	1	12	Mild, moderate or severe	Yes	_	I/-/III	CIDI-PHC: presence or absence of depressive episode
van den Brink et al. (2002)	269/-	18–65	GHQ-12	CIDI-PHC	1	12	Number of depressive symptoms	Yes	Yes	I/-/III	CIDI-PHC and 50% reduction in symptom severity: Full recovery in 6 months/Partial recovery or full recovery in 12 months/ No recovery
Lyness <i>et al.</i> (2002)	22/41	>59	CES-D	SCID	1	12	HAM-D	_	_	-/-/III	SCID I: MDD/MinD/ Subsyndromal depression/Non
Gaynes <i>et al.</i> (1999)	85/-	18–64	CES-D	Telephone DIS	4	12	CES-D	_	_	I/-/III	Telephone DIS: MDD/MinD/ Dysthymia/Non
Wagner <i>et al</i> . (2000)	66/75	18–64	CES-D	Telephone DIS	4	12	CES-D	-	-	I/-/III	Telephone DIS: MDD/ MinD/Dysthymia/Non
Oldehinkel et al. (2000)	54/32	17–65	30-GHQ; incident MDE lasting >3 months	PSE	3 and life-chart	42	PSE score	Yes	-	-/-/-	PSE: Case/non
Ormel <i>et al.</i> (1993)	52/27	17–65	30-GHQ; new cases	PSE	3	42	Case/ borderline case	-	-	I/-/-	PSE: Case/borderline case/non-specific symptoms/asymptomatic

Table 1. Prospective outcome studies in primary care with a follow-up of over 6 months, diagnostic interview and usual care arms in case of randomized clinical trials

De Almeida Fleck <i>et al.</i> (2005)	968/-	18–75	CES-D; new and/or untreated depression	CIDI	1	9	CES-D	-	Yes	I/-/III	CIDI, and CES-D >16: Complete remission/non
The usual care a	arms in rand	domized	l clinical trials								
Brown <i>et al.</i> (2000)	92/-	18–64		DIS, and HAMD >12	1	8	HAMD	-	-	I/II/III	HAMD <8: Recovered/ non-recovered
Koike <i>et al.</i> (2002)	217/226	>17	Stem items of CIDI	CIDI	1	12	CES-D	-	-	I/–/III	CES-D, Stem items of CIDI: Probable case/non
Willemse <i>et al.</i> (2004)	-/109	18–65	Instel screening instrument	Telephone CIDI	1	12	CES-D	-	-	-/-/-	Telephone CIDI: MDD/non
Unutzer <i>et al.</i> (2002)	612/283	>59	Prime-MD or referral	SCID	3	12	SCL-20		Yes	I/-/III	SCID, SCL-20 MDD/ treatment response/ complete remission
Bogner <i>et al.</i> (2005)	396/-	>59	CES-D	SCID	4	24	HAMD	-	-	-/-/III	HAMD <10 Remission/ treatment response/ non-remission
Simon (2000)	225/-	18-80	New treatment	SCID	7	24	HAMD	Yes	Yes	I/-/III	SCID, HAMD <8 MDD/ subthreshold depression/ remission
Lin <i>et al</i> . (1999)	53/-	18–80	New treatment; HSCL >0.75	SCL	1	19	HSCL	_	-	-/-/III	Telephone IDS, SCL MDD/ non
Wells <i>et al.</i> (2004)	443	>17	Stem items of CIDI	Telephone CIDI	6	57	-	-	-	-/-/III	Stem items of CIDI: Probable depressive disorder/non

MDD, Major depressive disorder; subMDD, subsyndromal depressive disorder; GHQ, General Health Questionnaire; CIDI-PHC, Composite International Diagnostic Interview – Primary Health Care Version; CES-D, Center for Epidemiologic Studies Depression Scale; SCID, Structured Clinical Interview for DSM; HAMD, Hamilton Depression Rating Scale; MinD, minor depression; DIS, Diagnostic Interview Schedule of the National Institute of Mental Health; MDE, major depressive episode; PSE, Present State Examination; CIDI, Composite International Diagnostic Interview; Prime-MD, Primary Care Evaluation of Mental Disorders; SCL, Symptom Checklist; HSCL, Hopkins Symptom Checklist; IDS, Inventory of Depressive Symptoms.

are informative to some extent, generalizability remains uncertain due to stringent inclusion and exclusion criteria and the necessity of patients to accept the randomization that render their patient populations not representative of typical patients. The wide variation in definition and assessment of remission in available studies also obscures the picture of possible partial recovery and residual symptoms. Only one naturalistic prospective study has reported recurrences in primary care, finding 40% of cases to have had a recurrence in 3.5 years (Oldehinkel et al. 2000). In an intervention study with a 1-year follow-up, recurrences occurred in one-third of patients (Lin et al. 1999). A follow-up using medical records suggested a recurrence rate of only 40% over 10 years (van Weel-Baumgarten et al. 1998); however, the shortcomings in detection and recording the diagnosis of depression in primary care may influence this estimation (Coyne et al. 1995; Harman et al. 2001). Overall, the outcome of depression in primary care is not well known in terms of prevalence of chronicity, relapses and recurrences, as well as residual symptoms.

Little is also known about the factors influencing the outcome of depression in primary care. The findings from the available studies are difficult to interpret because of methodological limitations, including inconsistent use of structured or semi-structured interviews for both MDD and co-morbid disorders, not taking into account the effects of additional co-morbid disorders or other possible predictors and not using a life-chart methodology - already a 'gold standard' in follow-up studies in psychiatric settings (Keller et al. 1987). Only one previous study exists with a life-chart methodology and information regarding predictors for duration of MDE (Oldehinkel et al. 2000). Moreover, although depression in primary care is highly comorbid (Vuorilehto et al. 2005), the impact of Axis I disorders on outcome has been investigated seldom (Ormel et al. 1993; Gaynes et al. 1999; Wagner et al. 2000; Lyness et al. 2002; van den Brink et al. 2002; Barkow et al. 2003; De Almeida Fleck et al. 2005). The influence of Axis II co-morbidity has been assessed in only one intervention study (Brown et al. 2000) (Table 1), and that of chronic medical conditions in only a few intervention studies (Brown et al. 2000; Simon, 2000; Koike et al. 2002; Wells et al. 2004). Due to focusing on only a narrow scope of possible predictors in cross-sectional outcome, the picture of predictors for the duration of depression or the risk of recurrence remains largely obscure.

In this naturalistic prospective study, we assessed the outcome of DSM-IV MDD and subsyndromal depressive disorders in a representative sample of 137 primary-care patients, among whom we had retrospectively found high rates of recurrence and chronicity in baseline assessment (Vuorilehto *et al.* 2005). Now, we investigated the outcome of this cohort prospectively. We overcame some major limitations of previous studies by using a life-chart methodology and semi-structured interviews for baseline diagnoses of all Axis I and II disorders, along with information on medical co-morbidity. We hypothesized that features of depression itself (severity, duration and recurrences before entry) and co-morbidity (Axis I, II and III disorders) would effectively predict chronicity and recurrence of depression.

Method

The Vantaa Primary Care Depression Study (PC-VDS) is a naturalistic and prospective cohort study on depressive disorders. Its study protocol was approved by the pertinent ethics committee in December 2001. The PC-VDS is a collaborative research project between the Department of Mental and Alcohol Research of the National Public Health Institute, Helsinki, and the Primary Health Care Organization of the City of Vantaa, Finland. The catchment area comprises a population of 63 400, served by 30 general practitioners with population-based responsibility. The baseline methodology is described in detail elsewhere (Vuorilehto *et al.* 2005).

Screening and baseline evaluation

In the first stage between 2 January and 31 December 2002, a total of 1119 consecutive patients aged 20-69 years received the screening questionnaire of the Primary Care Evaluation of Mental Disorders (PRIME-MD; Spitzer et al. 1994) in general practitioners' waiting rooms in two health centres. Altogether 375 patients had positive screen results, having answered 'yes' to either of the questions concerning depressed mood or anhedonia during the last month [(1) feeling down, depressed or hopeless or (2) having little interest or pleasure in doing things]. Over the telephone, we ensured that at least one core symptom of MDD was present according to the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID I/P; First et al. 2001). We excluded patients with diagnosed psychosis (other than depressive), bipolar or organic mood disorder, or who were currently receiving treatment in psychiatric care.

In the second stage, after receiving written informed consent, we interviewed all 175 potentially eligible patients face to face using the SCID-I/P with psychotic screen. Inclusion criteria were current (1) MDD, (2) dysthymia, (3) subsydromal MDD with two to four depression symptoms (minimum one core symptom) and lifetime MDD and (4) minor depression (MinD) otherwise similar to subsyndromal MDD, but without MDD history. Distress or functional impairment was required for all. Dysthymia was regarded as subsyndromal MDD or MinD according to a positive or negative history of MDD. The joint diagnostic reliability for current depressive disorders was 100% (κ = 1.0 for depression diagnoses). Patients who refused to participate in the study (15%) did not differ significantly in age or gender from those who consented (Vuorilehto *et al.* 2005).

Other research instruments

Current and lifetime psychiatric disorders were assessed with use of the SCID-I/P and the Structured Clinical Interview for DSM-IV Axis II Disorders (SCID-II; First et al. 1997). Observer and self-report scales included the 17-item Hamilton Depression Rating Scale (HAMD; Hamilton, 1960), the Scale for Suicide Ideation (Beck et al. 1979) and the Social and Occupational Functioning Assessment Scale for DSM-IV (Goldman et al. 1992). Self-report scales included the 21-item Beck Depression Inventory (BDI; Beck et al. 1961), the Beck Anxiety Inventory (BAI; Beck et al. 1988), the Beck Hopelessness Scale (Beck et al. 1974) and the Perceived Social Support Scale - Revised (Blumenthal et al. 1987). A self-report questionnaire, medical records and interview were used for chronic medical illnesses. Lifetime course for depression (age of onset, duration and recurrences before entry as well as chronicity of MDD according to DSM-IV criteria) was reconstructed from the interview and medical and psychiatric records.

Follow-up

The median time for 18-month interviews was 18.7 months (interquartile range 18.1-19.6). Of the 137 subjects initially included in the study, only three subjects (2%) dropped out from all follow-ups. In addition, two more subjects (2%) were missing at 6 months and altogether 10 subjects (7%) at 18 months. The diagnosis of four patients (3%) switched to bipolar disorder during the 18-month follow-up, and they were censored in the survival analysis at the time-point in the life-chart where the switch occurred. The final followup group in the survival analysis consisted of 134 patients, all with information from at least one of the three follow-up points: 89 patients with baseline MDD and 45 with baseline subsyndromal depressive disorder, of the latter 32 with a history of MDD and 13 with baseline MinD, thus without a history of MDD. Baseline characteristics along with antidepressant treatment of the 123 patients who completed the 18month follow-up (the four patients whose diagnoses switched to bipolar were not included) are shown in Table 2.

Outcome measures

After the baseline assessments, patients were prospectively followed-up with a life-chart-similar to the Vantaa Depression Study methodology (Melartin et al. 2004) - to determine the exact duration of the index episode and the timing of possible relapses and recurrences. To ensure accuracy of the life-chart, we gathered information at three different time-points: the BDI was rated at 3, 6 and 18 months, self-report scales were included at 3, 6 and 18 months, and the current diagnosis of depression was investigated by telephone at 6 months and face to face at 18 months by SCID-I interviews. In addition, observer scales were used at the 18-month assessment. We gathered all available data, including medical and psychiatric records, which were then integrated into the graphic life-chart. We also used probes related to important life events to improve the accuracy of the assessment of change points in the psychopathologic states. The life-chart was based on DSM-IV criteria and definitions.

The time after the baseline interview was divided into three kinds of periods: (1) state of MDE (five or more of the nine MDE criteria symptoms); (2) state of partial remission (one to four symptoms); or (3) state of full remission (no symptoms). In patients with baseline MDD, we calculated from the first baseline interview (1) the uninterrupted duration of the episode in the state of MDE (duration of MDE with full criteria) and (2) time to the first onset of state of full remission lasting at least two consecutive months (time to full remission). In patients with baseline subsyndromal depression, we calculated from the first baseline interview (1) time to the first onset of state of full remission lasting at least two consecutive months (time to full remission) and (2) time to the first onset of state of MDE with full criteria (time to MDE).

Definitions of remission and relapse followed DSM-IV criteria, and recurrence followed the DSM-IV definition for '296.3 \times MDD, Recurrent'. State of remission (further specified as full or partial) required at least two consecutive months in which MDE criteria were not met. Relapse referred to the return of symptoms fulfilling MDE criteria after a period of more than 2 weeks but less than 2 months with symptoms below the MDE threshold. Recurrence referred to the return of MDE after at least two consecutive months of partial or full remission.

Statistical methods

We used Kaplan–Meier survival curves to estimate the probability of remaining ill during the 18-month **Table 2.** Baseline characteristics of the 123 patients with depressive disorder followed-up for 18 months in The Vantaa Primary CareDepression Study

	MDD (<i>n</i> = 79)		SubE	SubD (<i>n</i> =31)		$\operatorname{MinD}(n = 13)$	
Categorical variables, <i>n</i> (%)							
Sociodemographic characteristics							
Male gender	20	(25)	5	(16)	5	(39)	
Married or co-habiting	43	(54)	17	(55)	6	(46)	
Currently employed	34	(43)	10	(32)	6	(46)	
History of MDD							
Recurrent MDD	55	(70)	21	(68)	_		
Chronic MDD	16	(20)	-		-		
Antidepressant treatment at entry	29	(37)	16	(52)	2	(15)	
Any co-morbid Axis I diagnosis	51	(65)	14	(45)	5	(36)	
Anxiety disorder	38	(48)	8	(25)	4	(31)	
Substance use disorder	13	(17)	1	(3)	1	(8)	
Any current Axis II diagnosis	44	(56)	15	(48)	3	(23)	
Cluster A personality disorder	4	(5)	1	(3)	-		
Cluster B personality disorder	25	(32)	6	(19)	1	(8)	
Cluster C personality disorder	26	(33)	10	(32)	2	(15)	
Current Axis III diagnosis							
Chronic medical illness	42	(53)	17	(55)	6	(46)	
Continuous variables, mean (s.d.)							
Age, years	46.2	(13.0)	45.6	(14.0)	42.4	(14.9)	
Age at onset of MDD, years	32.0	(14.5)	34.0	(13.1)	_	. ,	
Beck Depression Inventory	22.6	(9.7)	12.5	(6.9)	11.7	(6.2)	
Hamilton Depression Rating Scale	18.4	(4.8)	11.8	(4.2)	12.2	(2.9)	
Beck Anxiety Inventory	20.6	(13.4)	9.3	(5.5)	8.3	(7.4)	
Beck Hopelessness Scale	10.3	(5.2)	5.9	(5.1)	5.8	(2.8)	
Perceived Social Support Scale – Revised	41.7	(12.8)	44.7	(12.6)	45.8	(12.2)	
Social and Occupational Functioning Assessment Scale for DSM-IV	54.9	(10.9)	60.0	(12.1)	62.6	(8.7)	

MDD, Major depressive disorder; subMDD, subsyndromal depressive disorder with a history of MDD; MinD, minor depression without a history of MDD; s.D., standard deviation.

follow-up. The results were reported in probabilities of achieving a symptom state below the MDE criteria and of achieving full remission. Cox proportional hazards models were used in the multivariate analyses for predicting time (1) from baseline MDD to symptom state below MDE criteria, (2) and to full remission, and time (3) from symptom state below MDE criteria to a recurrent or relapsing MDE, (4) from baseline subsyndromal depressive disorder to a non-symptomatic state or (5) to a new MDE. In these analyses, censored data included subjects who had not achieved the focused symptom state by the end of the follow-up period or by the time they left the study or whose diagnosis switched to bipolar disorder. In analyses of recurrences, only those who completed the whole 18-month follow-up were included.


In our final models, we included variables on the basis of our primary hypothesis, but we also considered their clinical and statistical validity and relevance (e.g. state *versus* trait). The predetermined independent variables at baseline comprised BDI (alternatively HAMD), pre-entry chronicity (MDE duration of at least 24 months), history of former MDE, antidepressive medication at entry, BAI, substanceuse disorder, cluster A, B and C personality disorder, chronic medical illness, employment status and health centre. For the final models, we omitted the nonsignificant variables. All models were adjusted for age and gender. SPSS software (version 14.0; SPSS Inc., Chicago, IL, USA) was used.

Results

Baseline major depressive disorder

Outcome of index MDE

Of the 79 patients with baseline MDD who were followed-up for the entire 18-month period, slightly






Fig. 1. Survival analysis of remaining in major depressive episode (MDE) among primary-care patients with major depressive disorder (n = 89) (Kaplan–Meier survival curve).

more than one-third [38% (30/79)] achieved full remission of the index episode. Another third [37% (29/ 79)] achieved partial remission (one to four residual depressive symptoms), and a quarter [25% (20/79)] remained with full MDE criteria throughout the study.

Duration of index MDE with full criteria

The median duration of MDE with full criteria was 6.00 months [95% confidence interval (CI) 4.00–8.00] after entry (Fig. 1). In a Cox regression model, longer duration of MDE was predicted by higher severity of depression in baseline HAMD (Table 3) or BDI [in an alternative model, hazard ratio (HR) 1.95, p<0.001, 95% CI 1.03–1.09], as well as by baseline co-morbid substance-use disorder (Table 3). Other psychiatric or somatic co-morbidities or any sociodemographic characteristics at baseline did not predict duration of MDE.

Time to full remission after index MDE

In a Cox regression model, longer time to full remission was predicted only by older age and more severe symptoms of depression at baseline (Table 3).

Relapses and recurrences

Of the patients with baseline MDD, 75% (59/79) achieved a symptom state below full MDE criteria. In one-third [32% (19/59)], symptoms fulfilling MDE criteria returned, either in the state of partial remission [15% (9/59)] or in the state of already total remission

Table 3. Predictors of outcome among 85 patients with MDEin The Vantaa Primary Care Depression Study in a Coxregression model

Baseline characteristic	HR	95% CI	р						
Duration of the index MDE with full criteria									
Age, years	1.01	0.99–1.03							
Male gender	1.43	0.81 - 2.50							
Hamilton Depression	1.11	1.19 - 1.05	0.001						
Rating Scale score									
Co-morbid substance-use	3.05	1.31–7.12	0.01						
disorder									
Time to full remission									
Age, years	1.05	1.02 - 1.08	< 0.001						
Male gender	1.59	0.58-3.70							
Beck Depression	1.05	1.01 - 1.10	0.015						
Inventory score									
Interval from remission to first relapse or recurrence									
Age, years	0.98	0.94 - 1.02							
Male gender	0.64	0.20-2.00							
Beck Depression	0.93	0.88-0.99	0.022						
Inventory score									
Personality disorder	0.37	0.15-0.91	0.03						
cluster C									

MDE, Major depressive episode; HR, hazard ratio; CI, confidence interval.

[17% (10/59)]. Of these patients, 8% (5/59) relapsed immediately (return of criteria for MDE, after a period with symptoms below the MDE threshold exceeding 2 weeks, but less than 2 months), 27% (16/59) had a recurrence (return of MDE after at least two consecutive months of partial or full remission) and in 3% (2/59) both conditions occurred.

In a Cox regression model, longer time to first relapse or recurrence was predicted by milder depressive symptoms and by not having a cluster C personality disorder at baseline (Table 3).

Baseline subsyndromal depressive disorders

Outcome of the index subsyndromal symptom state

During the 18-month follow-up the index subsyndromal symptom state improved to a nonsymptomatic state in about half of the patients [55% (24/44)]. The subsyndromal state remained persistent with one to four depressive symptoms in one-fifth [20% ([9/44)], and proceeded to MDE in one-quarter of patients [25% (11/44)].

Time to change from subsyndromal symptom state

The median time from entry to a non-symptomatic state was 6.53 months (95% CI 3.63–9.43). In a Cox

regression model, slower improvement was predicted by chronic medical illness (HR 2.785, p = 0.031, 95% CI 1.10–7.05). Slower progress to an emerging or recurrent MDE was predicted by baseline diagnosis of MinD (never having suffered from MDD) (HR 15.08, p = 0.021, 95% CI 1.50–151.86).

Discussion

Our medium-term prospective life-chart study verified the chronic and recurrent nature of depression in primary care. Only one-quarter of patients with MDD achieved and maintained full remission for 18 months, while another quarter failed to remit at all. The remaining patients suffered either from residual symptoms or recurrences during follow-up. While severity of depression was the most robust predictor of recovery, presence of co-morbid substance-use disorders, chronic medical illness and cluster C personality disorders also contributed to adverse outcome.

The major strengths of this study comprise a medium-sized (n=137) cohort of primary-care patients with either MDD or subsyndromal depressive disorder, effectively representing the primary health care patients in a Finnish city, and use of structured interviews with excellent reliability for the diagnosis of MDD ($\kappa = 1.0$), plus information on all co-morbid Axis I, II, and medical disorders at baseline, although the reliability of co-morbid disorder diagnoses and outcome variables remains unknown. Moreover, the patients were followed-up using a life-chart. Besides diagnostic characteristics and symptom ratings, we included predictors from several other potentially relevant domains at baseline, such as functional status, perceived social support and treatment received. Finally, attrition is unlikely to have biased our findings, as 90% of the cases could be assessed face to face at least once after baseline, and for 98% some or all ratings were available.

However, some methodological choices need to be clarified. First, by using a screen at intake, we aimed to provide an accurate picture of the clinical caseload of depressive disorders, both recognized and unrecognized, met by primary-care doctors in everyday work. The probability that a depressive patient will appear in this kind of prevalence-based cohort is proportional both to the incidence of onsets and to the duration of the depression; therefore, compared with incidence-based studies, cases of long duration are enriched in our cohort (Cohen & Cohen, 1984). Moreover, as the patients were not recruited at similar points in the course of their depression, the duration of the episodes in follow-up are not comparable with results of incidence-based studies. Second, we investigated the outcome of depression by using a graphic life-chart, which is similar but not identical to the Longitudinal Interval Followup Evaluation (LIFE) methodology used in NIMH-CDS (Keller et al. 1992). We used probes related to important events when inquiring about change points in the psychopathologic state, BDI ratings at three time-points and patient records. Some underestimation or inaccuracy of reported symptoms may, however, have taken place due to possible recall bias. Unlike in the LIFE, we classified patients' follow-up time into periods compatible with DSM-IV MDE, partial remission and full remission. With use of rather stringent definitions in the DSM-IV, we found a cross-sectional full remission rate (26.6%) that falls in the lower end of remission rates (from 29% to 37%) of available outcome studies on prevalent cases (Gaynes et al. 1999; Wagner et al. 2000). Third, we deliberately confined ourselves to predictors of outcome that were present and recognizable to the doctor at intake. We thus disregarded all events during follow-up that may have influenced the course of depression, including many psychosocial factors together with the complex process of seeking, receiving and complying with treatment. The adequacy of treatment during follow-up is a subject of a further study. Finally, while the cohort probably represents Finnish urban and suburban primary health care patient populations well, the generalizability to rural or foreign patient populations remains unknown. To the extent that other studies have investigated the same characteristics in primary care, no major differences between our findings and those in other countries are apparent.

This longitudinal study revealed the adverse prognosis of MDD in primary care: only one-quarter of patients remained with a sustained favourable outcome and one-third of those with some remission experienced recurrence or relapse. As in previous cross-sectional outcome studies (Gaynes et al. 1999; Barkow et al. 2003; De Almeida Fleck et al. 2005), also large proportions of partial remission (37%) and chronic course (25%) emerged in our study. Remission appeared slowly; at 6 months, only half of the patients had shown some recovery. The duration of MDE has earlier been investigated in primary care in only a cohort of new patients, where the median duration was 8 months (Oldehinkel et al. 2000). Overall, our crosssectional findings were consistent with previous primary-care studies, although the life-charts also revealed apparent recurrences and fluctuations of symptoms alongside chronicity. In our view, this information is important for developing management of depression in primary health care towards the multifaceted collaborative care models, likely to be effective and already endorsed in some clinical guidelines (NICE, 2004; Gilbody *et al.* 2006).

Higher severity of depression was the main predictor for poor outcome. As in studies in the general population (Spijker et al. 2002) and in psychiatric patients (Keller et al. 1992; Mueller, 1996; Meyers et al. 2002; Melartin et al. 2004), baseline severity of depression was associated with both chronicity and relapses/recurrences. Moreover, to a lesser extent, comorbid substance-use disorders predicted chronic course of depression consistently with an earlier reported result of an univariate analysis in primary care (Barkow et al. 2003). To our knowledge, we were the first to investigate Axis II disorders as predictors of outcome in primary care. We found co-morbid cluster C personality disorders (avoidant, dependent, obsessive-compulsive) to predict early recurrences. Earlier, a general population survey (Johnson et al. 2005) reported a similar association, while in specialist care, cluster C personality disorders have mainly been associated with longer duration of MDE (Viinamaki et al. 2002; Farabaugh et al. 2005). Finally, chronic medical illnesses, a known predictor for adverse crosssectional outcome (Wagner et al. 2000; van den Brink et al. 2002), also formed a risk factor for slow recovery from subsyndromal depression in this cohort. However, some of our expectations were not fulfilled; co-morbid anxiety disorders, a strong predictor of slower recovery in specialized care (Parker, 2000; Melartin et al. 2004), were not a predictor of outcome in this study, neither were sociodemographic factors, other than age. In studies on psychiatric patients and in the general population (Mueller, 1996), controlling for depression severity has diminished the predictive power of sociodemographic factors. Overall, among primary-care patients with mild to moderate MDD, severity of depression served well as a predictor of outcome.

The follow-up of subsyndromal depressive disorders revealed the significance of lifetime history of MDD for expected outcome. While 'proper' MinD (without history of MDD in DSM-IV) seldom proceeded to MDE, an adverse progression of symptoms to a new MDE was seen in one-third of those who were in partial remission or in a potential prodromal phase of lifetime MDD. Overall, however, as in the few existing cross-sectional studies (Ormel et al. 1993; Wagner et al. 2000; Lyness et al. 2002), the group with subsyndromal depressive disorders had a better prognosis. They had at entry fewer co-morbid psychiatric disorders (Vuorilehto et al. 2005) and may therefore represent a group in a clinical subgroup of patients more likely to recover. In clinical decisionmaking, a history of previous MDD should not be ignored by primary-care doctors.

Conclusions

This prospective longitudinal investigation verified the longitudinally fluctuating course of depression in primary care, with high rates of recurrence and chronicity of depressive episodes. Severity of depressive symptoms and co-morbidity are important predictors also in primary care. Treatment of depression in primary care should be based on the management of a chronic disease in order to improve outcome.

Acknowledgements

This study has been funded by the Primary Health Care Organization of the City of Vantaa, and the National Public Health Institute, Helsinki, Finland.

Declaration of Interest

None.

References

- Barkow K, Maier W, Ustun TB, Gansicke M, Wittchen HU, Heun R (2003). Risk factors for depression at 12-month follow-up in adult primary health care patients with major depression: an international prospective study. *Journal of Affective Disorders* **76**, 157–169.
- Beck AT, Epstein N, Brown G, Steer RA (1988). An inventory for measuring clinical anxiety: psychometric properties. *Journal of Consulting and Clinical Psychology* 56, 893–897.
- Beck AT, Kovacs M, Weissman A (1979). Assessment of suicidal intention: the Scale for Suicide Ideation. *Journal of Consulting and Clinical Psychology* 47, 343–352.
- Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J (1961). An inventory for measuring depression. Archives of General Psychiatry 4, 561–571.
- Beck AT, Weissman A, Lester D, Trexler L (1974). The measurement of pessimism: the hopelessness scale. *Journal* of Consulting and Clinical Psychology **42**, 861–865.
- Blumenthal JA, Burg MM, Barefoot J, Williams RB, Haney T, Zimet G (1987). Social support, type A behavior, and coronary artery disease. *Psychosomatic Medicine* 49, 331–340.
- Bogner HR, Cary MS, Bruce ML, Reynolds 3rd CF, Mulsant B, Ten Have T, Alexopoulos GS (2005). The role of medical comorbidity in outcome of major depression in primary care: the PROSPECT study. *American Journal of Geriatric Psychiatry* **13**, 861–868.
- **Brown C, Schulberg HC, Prigerson HG** (2000). Factors associated with symptomatic improvement and recovery from major depression in primary care patients. *General Hospital Psychiatry* **22**, 242–250.
- Cohen P, Cohen J (1984). The clinician's illusion. Archives of General Psychiatry 41, 1178–1182.

Coyne JC, Schwenk TL, Fechner-Bates S (1995). Nondetection of depression by primary care physicians reconsidered. *General Hospital Psychiatry* **17**, 3–12.

De Almeida Fleck MP, Simon G, Herrman H, Bushnell D, Martin M, Patrick D (2005). Major depression and its correlates in primary care settings in six countries.
9-Month follow-up study. *British Journal of Psychiatry* 186, 41–47.

Eaton WW, Anthony JC, Gallo J, Cai G, Tien A, Romanoski A, Lyketsos C, Chen LS (1997). Natural history of Diagnostic Interview Schedule/DSM-IV major depression. The Baltimore Epidemiologic Catchment Area follow-up. *Archives of General Psychiatry* 54, 993–999.

Farabaugh A, Fava M, Mischoulon D, Sklarsky K, Petersen T, Alpert J (2005). Relationships between major depressive disorder and comorbid anxiety and personality disorders. *Comprehensive Psychiatry* **46**, 266–271.

First M, Spitzer R, Gibbon M (1997). Structured Clinical Interview for DSM-IV Personality Disorders (SCID-II). American Psychiatric Press, Inc.: Washington, DC.

First M, Spitzer R, Gibbon M (2001). Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition with Psychotic Screen. New York State Psychiatric Institute: New York.

Gaynes BN, Magruder KM, Burns BJ, Wagner HR, Yarnall KS, Broadhead WE (1999). Does a coexisting anxiety disorder predict persistence of depressive illness in primary care patients with major depression? *General Hospital Psychiatry* **21**, 158–167.

Gilbody S, Bower P, Fletcher J, Richards D, Sutton AJ (2006). Collaborative care for depression: a cumulative meta-analysis and review of longer-term outcomes. *Archives of Internal Medicine* **166**, 2314–2321.

Goldman HH, Skodol AE, Lave TR (1992). Revising axis V for DSM-IV: a review of measures of social functioning. *American Journal of Psychiatry* **149**, 1148–1156.

Hamilton M (1960). A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry 23, 56–62.

Harman JS, Schulberg HC, Mulsant BH, Reynolds 3rd CF (2001). The effect of patient and visit characteristics on diagnosis of depression in primary care. *Journal of Family Practice* **50**, 1068.

Hasin DS, Goodwin RD, Stinson FS, Grant BF (2005). Epidemiology of major depressive disorder: results from the National Epidemiologic Survey on Alcoholism and Related Conditions. *Archives of General Psychiatry* **62**, 1097–1106.

Johnson JG, Cohen P, Kasen S, Brook JS (2005). Personality disorder traits associated with risk for unipolar depression during middle adulthood. *Psychiatry Research* 136, 113–121.

Keller MB, Lavori PW, Friedman B, Nielsen E, Endicott J, McDonald-Scott P, Andreasen NC (1987). The Longitudinal Interval Follow-up Evaluation. A comprehensive method for assessing outcome in prospective longitudinal studies. *Archives of General Psychiatry* 44, 540–548.

Keller MB, Lavori PW, Mueller TI, Endicott J, Coryell W, Hirschfeld RM, Shea T (1992). Time to recovery, chronicity, and levels of psychopathology in major depression. A 5-year prospective follow-up of 431 subjects. Archives of General Psychiatry **49**, 809–816.

Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, Rush AJ, Walters EE, Wang PS (2003). The epidemiology of major depressive disorder : results from the National Comorbidity Survey Replication (NCS-R). Journal of the American Medical Association 289, 3095–3105.

Koike AK, Unutzer J, Wells KB (2002). Improving the care for depression in patients with comorbid medical illness. *American Journal of Psychiatry* **159**, 1738–1745.

Lin EH, Simon GE, Katon WJ, Russo JE, Von Korff M, Bush TM, Ludman EJ, Walker EA (1999). Can enhanced acute-phase treatment of depression improve long-term outcomes? A report of randomized trials in primary care. *American Journal of Psychiatry* **156**, 643–645.

Lyness JM, Caine ED, King DA, Conwell Y, Duberstein PR, Cox C (2002). Depressive disorders and symptoms in older primary care patients: one-year outcomes. *American Journal of Geriatric Psychiatry* **10**, 275–282.

Melartin TK, Rytsala HJ, Leskela US, Lestela-Mielonen PS, Sokero TP, Isometsa ET (2004). Severity and comorbidity predict episode duration and recurrence of DSM-IV major depressive disorder. *Journal of Clinical Psychiatry* 65, 810–819.

Meyers BS, Sirey JA, Bruce M, Hamilton M, Raue P, Friedman SJ, Rickey C, Kakuma T, Carroll MK, Kiosses D, Alexopoulos G (2002). Predictors of early recovery from major depression among persons admitted to community-based clinics: an observational study. *Archives of General Psychiatry* **59**, 729–735.

Moussavi S, Chatterji S, Verdes E, Tandon A, Patel V, Ustun B (2007). Depression, chronic diseases, and decrements in health: results from the World Health Surveys. *Lancet* **370**, 851–858.

Mueller T (1996). Recovery after 5 years of unremitting major depressive disorder. *Archives of General Psychiatry* 53, 794–799.

NICE (2004). Depression: management of depression in primary and secondary care (http://www.nice.org.uk/ CG023). National Institute for Health and Clinical Excellence. Accessed 10 November 2007.

Oldehinkel AJ, Ormel J, Neeleman J (2000). Predictors of time to remission from depression in primary care patients: do some people benefit more from positive life change than others? *Journal of Abnormal Psychology* **109**, 299–307.

Ormel J, Oldehinkel T, Brilman E, vanden Brink W (1993). Outcome of depression and anxiety in primary care. A three-wave 3 1/2-year study of psychopathology and disability. *Archives of General Psychiatry* **50**, 759–766.

Parker G (2000). Predictors of 1-year outcome in depression. *Australian and New Zealand Journal of Psychiatry* **34**, 56–64.

Pirkola SP, Isometsa E, Suvisaari J, Aro H, Joukamaa M, Poikolainen K, Koskinen S, Aromaa A, Lonnqvist JK (2005). DSM-IV mood-, anxiety- and alcohol use disorders and their comorbidity in the Finnish general population – results from the Health 2000 Study. *Social Psychiatry and Psychiatric Epidemiology* **40**, 1–10. Simon GE (2000). Long-term prognosis of depression in primary care. Bulletin of the World Health Organization 78, 439–445.

Spijker J, Bijl RV, de Graaf R, Nolen WA (2001). Care utilization and outcome of DSM-III-R major depression in the general population. Results from the Netherlands Mental Health Survey and Incidence Study (NEMESIS). *Acta Psychiatrica Scandinavica* 104, 19–24.

Spijker J, de Graaf R, Bijl RV, Beekman AT, Ormel J, Nolen WA (2002). Duration of major depressive episodes in the general population : results from The Netherlands Mental Health Survey and Incidence Study (NEMESIS). British Journal of Psychiatry 181, 208–213.

Spitzer RL, Williams JB, Kroenke K, Linzer M, deGruy 3rd FV, Hahn SR, Brody D, Johnson JG (1994). Utility of a new procedure for diagnosing mental disorders in primary care. The PRIME-MD 1000 study. *Journal of the American Medical Association* 272, 1749–1756.

Unutzer J, Katon W, Callahan CM, Williams Jr. JW, Hunkeler E, Harpole L, Hoffing M, Della Penna RD, Noel PH, Lin EH, Arean PA, Hegel MT, Tang L, Belin TR, Oishi S, Langston C (2002). Collaborative care management of late-life depression in the primary care setting: a randomized controlled trial. *Journal of the American Medical Association* **288**, 2836–2845.

van den Brink RH, Ormel J, Tiemens BG, Smit A, Jenner JA, van der Meer K, van Os TW (2002). Predictability of the one-year course of depression and generalized anxiety in primary care. *General Hospital Psychiatry* 24, 156–163.

van Weel-Baumgarten E, van den Bosch W, van den Hoogen H, Zitman FG (1998). Ten year follow-up of depression after diagnosis in general practice. *British Journal of General Practice* **48**, 1643–1646.

Viinamaki H, Hintikka J, Honkalampi K, Koivumaa-Honkanen H, Kuisma S, Antikainen R, Tanskanen A, Lehtonen J (2002). Cluster C personality disorder impedes alleviation of symptoms in major depression. *Journal of Affective Disorders* **71**, 35–41.

Vuorilehto M, Melartin T, Isometsa E (2005). Depressive disorders in primary care: recurrent, chronic, and co-morbid. *Psychological Medicine* **35**, 673–682.

Wagner HR, Burns BJ, Broadhead WE, Yarnall KS, Sigmon A, Gaynes BN (2000). Minor depression in family practice: functional morbidity, co-morbidity, service utilization and outcomes. *Psychological Medicine* **30**, 1377–1390.

Wells K, Sherbourne C, Schoenbaum M, Ettner S, Duan N, Miranda J, Unutzer J, Rubenstein L (2004). Five-year impact of quality improvement for depression: results of a group-level randomized controlled trial. *Archives of General Psychiatry* **61**, 378–386.

Willemse GR, Smit F, Cuijpers P, Tiemens BG (2004). Minimal-contact psychotherapy for sub-threshold depression in primary care. Randomised trial. *British Journal of Psychiatry* **185**, 416–421.